Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged over 18 years
- People who have been diagnosed with primary lung cancer confirmed by a tissue sample (biopsy)
- People who have brain metastases (cancer that has spread to the brain), whether confirmed by tissue sample or not
- People whose brain metastases have been treated with radiation therapy
- People who are enrolled in a treatment plan for brain metastases using whole-brain radiation, stereotactic radiation, or gamma-knife radiation
- People whose follow-up MRI scan has shown that one or more brain metastases lesions have grown or changed in size
- People who are enrolled in a social security (health insurance) scheme
Who may not be able to join:
- People who have indicated they do not wish to take part in the study
- People for whom MRI scans are not medically safe (for example, due to certain implants or devices)
- People who have declined to have imaging performed
- People receiving state medical aid, unless a specific exemption applies (confirm with trial site)
- People with severe cognitive difficulties that would prevent them from giving informed consent
- People who are under legal guardianship or who are currently detained
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Augustin Gaudemer, MD, Assistance Publique - Hôpitaux de Paris
Phone: 01 40 25 76 13
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Visually significant hyperperfusion on normalized cerebral blood flow mapping generated from T2* infusion data with injection, confirmed by quantitative measurement of a ratio > 2.5 between tumor DSC and contralateral white matter.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.